Diagnostics of Coronavirus Disease 2019 Cardiovascular Complications

Enrolling by invitationOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

November 30, 2025

Conditions
COVID-19Endothelial FunctionDiastolic DysfunctionOxygen ConsumptionQuality of LifeExercise Tolerance
Interventions
DIAGNOSTIC_TEST

"Portable cardiac monitor CardioQvark"

"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."

DIAGNOSTIC_TEST

Cardiorespiratory stress test

Cardiorespiratory stress testing with gas analysis using the Quark CPET diagnostic system (COSMED, Italy). The study protocol will consist of 4 phases: rest, warm-up, exercise and recovery. During the load phase, a ramp protocol will be used with a stepped load from 10 to 25 W/min. The increase in power will be calculated individually before the start of the study so that the test lasts 8-12 minutes until complete muscle failure.

DIAGNOSTIC_TEST

Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer

The analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)

Trial Locations (1)

119991

"I.M. Sechenov First Moscow State Medical University (Sechenov University)ogy, Center Digital biodesign and personalized healthcare)", Moscow

All Listed Sponsors
lead

I.M. Sechenov First Moscow State Medical University

OTHER